IL17A and influenza: In conclusion, our study suggested that TLR4, CD14, MyD88, NF-κB p65, HIF1 α, VEGF, IL17A, and IL6 in the TLR4/NF-κB p65 signaling pathway and HIF-1α/IL17 signaling pathway may be the key targets for the identified active compounds of HSSD to treat influenza by inhibiting inflammatory responses.